Fig. 5

Effects of chemo-immunotherapy treatments based on lurbinectedin, ecubectedin and PM54 in patient-derived immune-xenografts. MPM#1 (epithelioid, BAP1⁺) and MPM#7 (sarcomatoid, BAP1⁻) cells were implanted s.c. in 6-week-old female Hu-CD34⁺ mice and treated as reported under Materials and Methods. (A). Tumor volumes growth and (B) median tumor volume on day 21 (n = 4 mice/group). (C) Percentage of Mo-MDSC, CD8⁺T-lymphocytes and TAM2 infiltrating the tumors measured by flow cytometry after tumor excision and dissociation. Pt + PMX, cisplatin plus pemetrexed. For both panels: *p < 0.05